Diabetes-associated changes and role of Nε-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction

Peptides

Volumn 31, Issue 2, 2010, Pages 346-353

  Matsumoto, Takayuki ^a   Ozawa, Yuta ^a   Taguchi, Kumiko ^a   Kobayashi, Tsuneo ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Big ET 1; CML; Coronary artery; Diabetes; Endothelin; Perfused heart

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BIG ENDOTHELIN 1; PHOSPHORAMIDON; STREPTOZOCIN; THIORPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DOSE RESPONSE; HEART PERFUSION; MALE; NONHUMAN; PATHOGENESIS; PERFUSION PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BENZOFURANS; BLOOD GLUCOSE; BODY WEIGHT; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN-1; ENZYME INHIBITORS; GLYCOPEPTIDES; HEART; LIPIDS; LYSINE; MALE; METALLOENDOPEPTIDASES; MYOCARDIUM; OLIGOPEPTIDES; ORGAN SIZE; PEPTIDES, CYCLIC; PERFUSION; PHOSPHONIC ACIDS; PIPERIDINES; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; THIORPHAN; VASOCONSTRICTION;

RATTUS;

EID: 73949125537     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.11.029     Document Type: Article

References (58)

1. Baidoshvili A., Niessen H.W., Stooker W., Huybregts R.A., Hack C.E., Rauwerda J.A., et al. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis 174 (2004) 287-292
2. Berg T.J., Clausen J.T., Torjesen P.A., Dahl-Jorgensen K., Bangstad H.J., and Hanssen K.F. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 21 (1998) 1997-2002
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
4. Collier A., Leach J.P., McLellan A., Jardine A., Morton J.J., and Small M. Plasma endothelinlike immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 15 (1992) 1038-1040
5. Erbas T., Erbas B., Kabakci G., Aksoyek S., Koray Z., and Gedik O. Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus. Clin Cardiol 23 (2000) 259-263
6. Fecteau M.H., Honore J.C., Plante M., Labonte J., Rae G.A., and D'Orleans-Juste P. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension 46 (2005) 87-92
7. Fujita K., Matsumura Y., Kita S., Hisaki K., Takaoka M., and Morimoto S. Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney. Hypertension 24 (1994) 227-233
8. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
9. Goto K., Hama H., and Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 72 (1996) 261-290
10. Hisaki K., Matsumura Y., Maekawa H., Fujita K., Takaoka M., and Morimoto S. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme. Am J Physiol 266 (1994) H422-H428
11. Horie K., Miyata T., Maeda K., Miyata S., Sugiyama S., Sakai H., et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100 (1997) 2995-3004
12. Jeng A.Y. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Curr Opin Invest Drugs 4 (2003) 1076-1081
13. Kamata K., Miyata N., and Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 97 (1989) 614-618
14. Kamata K., Ozawa Y., Kobayashi T., and Matsumoto T. Effect of long-term streptozotocin-induced diabetes on coronary vasoconstriction in isolated perfused rat heart. J Smooth Muscle Res 44 (2008) 177-188
15. Kamata K., Ozawa Y., Kobayashi T., and Matsumoto T. Effect of N-epsilon-(carboxymethyl)lysine on coronary vasoconstriction in isolated perfused hearts from control and streptozotocin-induced diabetic rats. J Smooth Muscle Res 45 (2009) 125-137
16. Kanie N., Matsumoto T., Kobayashi T., and Kamata K. Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br J Pharmacol 140 (2003) 23-32
17. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag 4 (2008) 1061-1068
18. Kashiwabara T., Inagaki Y., Ohta H., Iwamatsu A., Nomizu M., Morita A., et al. Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett 247 (1989) 73-76
19. Keynan S., Khamaisi M., Dahan R., Barnes K., Jackson C.D., Turner A.J., et al. Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 41 (2004) 131-140
20. Khamaisi M., Dahan R., Hamed S., Abassi Z., Heyman S.N., and Raz I. Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology 150 (2009) 1440-1449
21. Kimura S., Kasuya Y., Sawamura T., Shinimi O., Sugita Y., Yanagisawa M., et al. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol 13 (1989) S5-7
22. Kobayashi T., Matsumoto T., and Kamata K. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent relaxation seen in streptozotocin-induced diabetic rats. Br J Pharmacol 131 (2000) 231-238
23. Kobayashi T., Nogami T., Taguchi K., Matsumoto T., and Kamata K. Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. Br J Pharmacol 155 (2008) 974-983
24. Makino A., and Kamata K. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 123 (1998) 1065-1072
25. Makino A., Oda S., and Kamata K. Mechanisms underlying increased release of endothelin-1 from aorta in diabetic rats. Peptides 22 (2001) 639-645
26. Matsumoto T., Ishida K., Taguchi K., Kobayashi T., and Kamata K. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery. Peptides 30 (2009) 1729-1734
27. Matsumoto T., Ishida K., Nakayama N., Kobayashi T., and Kamata K. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 296 (2009) H1388-H1397
28. Matsumoto T., Kakami M., Kobayashi T., and Kamata K. Gender differences in vascular reactivity to endothelin-1 (1-31) in mesenteric arteries from diabetic mice. Peptides 29 (2008) 1338-1346
29. Matsumoto T., Kakami M., Noguchi E., Kobayashi T., and Kamata K. Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 293 (2007) H1480-H1490
30. Matsumoto T., Kobayashi T., and Kamata K. Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 285 (2003) H283-H291
31. Matsumoto T., Kobayashi T., and Kamata K. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res 44 (2008) 41-55
32. Matsumoto T., Kobayashi T., Wakabayashi K., and Kamata K. Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 289 (2005) H1933-H1940
33. Matsumoto T., Nakayama N., Ishida K., Kobayashi T., and Kamata K. Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. J Pharmacol Exp Ther 329 (2009) 324-334
34. Matsumoto T., Noguchi E., Kobayashi T., and Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med 42 (2007) 993-1007
35. Matsumoto T., Ozawa Y., Taguchi K., Kobayashi T., and Kamata K. Chronic treatment with losartan (angiotensin II type 1 receptor antagonist) normalizes enhanced acetylcholine-induced coronary vasoconstriction in isolated perfused heart from type 2 diabetic OLETF rat. J Smooth Muscle Res 45 (2009) 197-208
36. Matsumoto T., Wakabayashi K., Kobayashi T., and Kamata K. Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am J Physiol Heart Circ Physiol 287 (2004) H1064-H1071
37. Matsumoto T., Yoshiyama S., Kobayashi T., and Kamata K. Mechanisms underlying enhanced contractile response to endothelin-1 in diabetic rat basilar artery. Peptides 25 (2004) 1985-1994
38. McMahon E.G., Palomo M.A., Moore W.M., McDonald J.F., and Stern M.K. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 88 (1991) 703-707
39. Miyauchi T., and Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61 (1999) 391-415
40. Park J.Y., Takahara N., Gabriele A., Chou E., Naruse K., Suzuma K., et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49 (2000) 1239-1248
41. Petersson J., Hanson G.C., Lindberg B.F., and Hogestatt Z.D. Contractile effect of big endothelin-1 and its conversion to endothelin-1 in rabbit cerebral arteries. Naunyn Schmiedebergs Arch Pharmacol 354 (1996) 656-661
42. Pollock D.M., Divish B.J., Milicic I., Novosad E.I., Burres N.S., and Opgenorth T.J. In vivo characterization of a phosphoramidon-sensitive endothelin-converting enzyme in the rat. Eur J Pharmacol 231 (1993) 459-464
43. Quehenberger P., Bierhaus A., Fasching P., Muellner C., Klevesath M., Hong M., et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49 (2000) 1561-1570
44. Reddy S., Bichler J., Wells-Knecht K.J., Thorpe S.R., and Baynes J.W. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34 (1995) 10872-10878
45. Rubanyi G.M., and Polokoff M.A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46 (1994) 325-415
46. Sakata N., Imanaga Y., Meng J., Tachikawa Y., Takebayashi S., Nagai R., et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 142 (1999) 67-77
47. Schleicher E.D., Wagner E., and Nerlich A.G. Increased accumulation of the glycation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99 (1997) 457-468
48. Schneider M.P., Boesen E.I., and Pollock D.M. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47 (2007) 731-759
49. Smit A.J., and Lutgers H.L. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11 (2004) 2767-2784
50. Takahashi K., Ghatei M.A., Lam H.C., O'Halloran D.J., and Bloom S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33 (1990) 306-310
51. Tickerhoof M.M., Farrell P.A., and Korzick D.H. Alterations in rat coronary vasoreactivity and vascular protein kinase C isoforms in type 1 diabetes. Am J Physiol Heart Circ Physiol 285 (2003) H2694-H2703
52. Tirapelli C.R., Fecteau M.H., Honore J.C., Legros E., Gobeil F., and D'Orleans-Juste P. Enzymatic pathways involved in the generation of endothelin-1(1-31) from exogenous big endothelin-1 in the rabbit aorta. Br J Pharmacol 148 (2006) 527-535
53. Tsunoda K., Abe K., Sato T., Yokosawa S., and Yoshinaga K. Decreased conversion of big endothelin-1 to endothelin-1 in patients with diabetes mellitus. Clin Exp Pharmacol Physiol 18 (1991) 731-732
54. Turner A.J., and Murphy L.J. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 51 (1996) 91-102
55. Verma S., Arikawa E., Lee S., Dumont A.S., Yao L., and McNeill J.H. Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol 80 (2002) 980-986
56. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95 (2004) 233-238
57. Yamauchi T., Ohnaka K., Takayanagi R., Umeda F., and Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 267 (1990) 16-18
58. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415